4.6 Article

Autophagy, Inflammation and Innate Immunity in Inflammatory Myopathies

期刊

PLOS ONE
卷 9, 期 11, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0111490

关键词

-

资金

  1. Italian Ministry of Health
  2. Associazione Italiana Miastenia e Malattie Immunodegenerative-Amici del Besta Onlus

向作者/读者索取更多资源

Autophagy has a large range of physiological functions and its dysregulation contributes to several human disorders, including autoinflammatory/autoimmune diseases such as inflammatory myopathies (IIMs). In order to better understand the pathogenetic mechanisms of these muscular disorders, we sought to define the role of autophagic processes and their relation with the innate immune system in the three main subtypes of IIM, specifically sporadic inclusion body myositis (sIBM), polymyositis (PM), dermatomyositis (DM) and juvenile dermatomyositis (JDM). We found that although the mRNA transcript levels of the autophagy-related genes BECN1, ATG5 and FBXO32 were similar in IIM and controls, autophagy activation in all IIM subgroups was suggested by immunoblotting results and confirmed by immunofluorescence. TLR4 and TLR3, two potent inducers of autophagy, were highly increased in IIM, with TLR4 transcripts significantly more expressed in PM and DM than in JDM, sIBM and controls, and TLR3 transcripts highly up-regulated in all IIM subgroups compared to controls. Co-localization between autophagic marker, LC3, and TLR4 and TLR3 was observed not only in sIBM but also in PM, DM and JDM muscle tissues. Furthermore, a highly association with the autophagic processes was observed in all IIM subgroups also for some TLR4 ligands, endogenous and bacterial HSP60, other than the high-mobility group box 1 (HMGB1). These findings indicate that autophagic processes are active not only in sIBM but also in PM, DM and JDM, probably in response to an exogenous or endogenous 'danger signal'. However, autophagic activation and regulation, and also interaction with the innate immune system, differ in each type of IIM. Better understanding of these differences may lead to new therapies for the different IIM types.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen

Silvia Bonanno, Riccardo Zanin, Luca Bello, Irene Tramacere, Virginia Bozzoni, Luca Caumo, Manfredi Ferraro, Sara Bortolani, Gianni Soraru, Mauro Silvestrini, Veria Vacchiano, Mara Turri, Raffaella Tanel, Rocco Liguori, Michela Coccia, Renato Emilio Mantegazza, Tiziana Mongini, Elena Pegoraro, Lorenzo Maggi

Summary: This study retrospectively evaluated the quality of life (QoL) in adult patients with spinal muscular atrophy (SMA) during nusinersen treatment. The results showed that the QoL significantly improved in all domains except for muscle locking and pain. The study also found that emotions and social relationships were more relevant for females compared to males, and social relationships were affected by longer disease duration. Activities improved more in non-walker patients. The HFMSE and RULM motor function assessments also significantly improved.

JOURNAL OF NEUROLOGY (2022)

Letter Clinical Neurology

Reply to the Letter to the Editor in response to Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis

Christos Stergiou, Rhys Williams, Jennifer R. R. Fleming, Vasiliki Zouvelou, Elpinickie Ninou, Francesca Andreetta, Elena Rinaldi, Ornella Simoncini, Renato Mantegazza, Julius Bogomolovas, John Tzartos, Siegfried Labeit, Olga Mayans, Socrates Tzartos

Summary: Myasthenia gravis is an autoimmune disease caused by antibodies targeting the neuromuscular junction of skeletal muscles. The major autoantigen is nicotinic acetylcholine receptor. Thymus and thymoma play critical roles in the mechanisms and management of the disease. This study focused on the localization of titin epitopes to develop more specific anti-titin diagnostics.

BIOMEDICINES (2023)

Article Biotechnology & Applied Microbiology

Ravulizumab for the treatment of myasthenia gravis

Fiammetta Vanoli, Renato Mantegazza

Summary: Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction. Current treatments rely on nonselective immunosuppression, but have significant side effects and some patients are refractory. Ravulizumab, a selective immunosuppressive drug, has shown promising results in a randomized-controlled study (CHAMPION MG).

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Letter Pharmacology & Pharmacy

Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis

Fiammetta Vanoli, Renato Mantegazza

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Article Biochemistry & Molecular Biology

MiR-146a in ALS: Contribution to Early Peripheral Nerve Degeneration and Relevance as Disease Biomarker

Eleonora Giagnorio, Claudia Malacarne, Paola Cavalcante, Letizia Scandiffio, Marco Cattaneo, Viviana Pensato, Cinzia Gellera, Nilo Riva, Angelo Quattrini, Eleonora Dalla Bella, Giuseppe Lauria, Renato Mantegazza, Silvia Bonanno, Stefania Marcuzzo

Summary: Amyotrophic lateral sclerosis (ALS) is characterized by the loss of upper and lower motor neurons (UMNs, LMNs) and miR-146a dysregulation may contribute to the pathogenesis of ALS. In this study, miR-146a levels were increased in ALS peripheral nerves and decreased in the serum of ALS patients, suggesting its potential as a diagnostic and prognostic biomarker for the disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Clinical Neurology

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Andreas Meisel, Djillali Annane, Tuan Vu, Renato Mantegazza, Masahisa Katsuno, Rasha Aguzzi, Glen Frick, Laura F. Gault, James Howard Jr

Summary: This study analyzed the interim results of an ongoing open-label extension study to evaluate the long-term treatment effects of ravulizumab in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The findings showed that ravulizumab demonstrated sustained efficacy and safety in improving the disease condition of patients.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores

Sarah Dewilde, M. F. Janssen, Nafthali H. Tollenaar, Fiammetta Vanoli, Rita Frangiamore, Glenn Phillips, Sandra Paci, Renato Mantegazza, Andreas Meisel, Frauke Stascheit

Summary: This study aims to assess the concordance between self- and physician-reported MG-ADL scores. The results show that patients and neurologists have a concordant assessment of the patient's MG symptoms when using the MG-ADL scale. This evidence supports patient self-administration of the MG-ADL in clinical practice and research.

MUSCLE & NERVE (2023)

Article Biochemistry & Molecular Biology

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization

Nicola Iacomino, Letizia Scandiffio, Fabio Conforti, Erika Salvi, Maria Cristina Tarasco, Federica Bortone, Stefania Marcuzzo, Ornella Simoncini, Francesca Andreetta, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Carlo Antozzi, Renato Mantegazza, Tommaso Martino De Pas, Paola Cavalcante

Summary: The thymus plays a role in the development of autoimmunity in myasthenia gravis (MG) patients. Changes in gene expression related to muscle autoantigens, such as AChR α subunit (CHRNA1) and autoimmune regulator (AIRE), as well as tumor-related muscle-like proteins (NEFM, HSP60, RYR1, RYR3, TTN), were observed in MG thymuses with hyperplasia and thymoma. These findings suggest a potential mechanism for the development of MG in thymomas involving altered autoantigen expression and molecular mimicry.

BIOMEDICINES (2023)

Article Immunology

Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies

Cristina Cappelletti, Raffaella Brugnoni, Silvia Bonanno, Francesca Andreetta, Franco Salerno, Eleonora Canioni, Gaetano Nicola Alfio Vattemi, Paola Tonin, Renato Mantegazza, Lorenzo Maggi

Summary: This study aimed to investigate whether the immune system could serve as a source of potential biomarkers for stratifying immune-mediated necrotizing myopathies (IMNMs) subtypes. The results showed a significant preponderance of M1 macrophages in muscle samples of both SRP+ and HMGCR(+) IMNM patients. Furthermore, TLR4 and IL-7 were identified as potential immune biomarkers for differentiating between SRP+ and HMGCR+ patients.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Article Clinical Neurology

Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study

Vera Bril, James F. Howard Jr, Chafic Karam, Jan L. De Bleecker, Hiroyuki Murai, Kimiaki Utsugisawa, Peter Ulrichts, Edward Brauer, Sihui Zhao, Renato Mantegazza, Tuan Vu, ADAPT Study Grp

Summary: Efgartigimod is beneficial in improving muscle function and strength across all muscle groups in patients with gMG by reducing IgG concentration and showing significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Human Mutated MYOT and CRYAB Genes Cause a Myopathic Phenotype in Zebrafish

Elena Cannone, Valeria Guglielmi, Giulia Marchetto, Chiara Tobia, Barbara Gnutti, Barbara Cisterna, Paola Tonin, Alessandro Barbon, Gaetano Vattemi, Marco Schiavone

Summary: Myofibrillar myopathies (MFMs) are a group of hereditary neuromuscular disorders characterized by myofibrillar derangement, Z-disk disintegration, and protein aggregation. Mutations in genes encoding structural proteins or molecular chaperones are implicated in MFM pathogenesis. In this study, transgenic zebrafish overexpressing mutant MYOT or CRYAB genes showed severe morphological defects and protein aggregation, resembling human myofibrillar myopathy. These findings suggest that zebrafish can serve as a useful model for studying the pathogenesis of MFM and identifying potential therapeutic targets.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Letter Clinical Neurology

Efgartigimod improves triple-negative myasthenia gravis

Rita Frangiamore, Elena Rinaldi, Fiammetta Vanoli, Francesca Andreetta, Renato Mantegazza, Carlo Antozzi

NEUROLOGICAL SCIENCES (2023)

Review Health Care Sciences & Services

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis

Carlo Antozzi, Renato Mantegazza

Summary: Myasthenia gravis is an autoimmune disorder that causes muscle weakness and fatigue. Standard therapies have limitations and there is a need for targeted treatments. Ravulizumab, a long-acting complement inhibitor, has shown effective and sustained improvement in patients with myasthenia gravis.

PATIENT-RELATED OUTCOME MEASURES (2023)

暂无数据